United Therapeutics ROE 2012-2025 | UTHR

Current and historical return on equity (ROE) values for United Therapeutics (UTHR) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
United Therapeutics ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2025-09-30 $1.27B $6.59B 18.83%
2025-06-30 $1.24B $7.17B 18.73%
2025-03-31 $1.21B $6.81B 19.32%
2024-12-31 $1.20B $6.44B 20.27%
2024-09-30 $1.11B $6.10B 19.22%
2024-06-30 $1.07B $5.70B 18.83%
2024-03-31 $1.05B $5.34B 18.73%
2023-12-31 $0.99B $5.99B 17.72%
2023-09-30 $0.90B $5.71B 17.11%
2023-06-30 $0.87B $5.41B 17.51%
2023-03-31 $0.73B $5.12B 15.49%
2022-12-31 $0.73B $4.80B 16.29%
2022-09-30 $0.71B $4.56B 16.62%
2022-06-30 $0.63B $4.32B 15.50%
2022-03-31 $0.69B $4.18B 17.64%
2021-12-31 $0.48B $3.96B 12.80%
2021-09-30 $0.46B $3.83B 12.94%
2021-06-30 $0.47B $3.64B 13.69%
2021-03-31 $0.41B $3.45B 12.26%
2020-12-31 $0.52B $3.40B 16.19%
2020-09-30 $0.47B $3.28B 15.50%
2020-06-30 $0.43B $3.09B 14.91%
2020-03-31 $0.53B $2.95B 19.19%
2019-12-31 $-0.11B $2.78B -4.05%
2019-09-30 $-0.09B $2.72B -3.58%
2019-06-30 $-0.12B $2.56B -4.56%
2019-03-31 $-0.15B $2.32B -5.79%
2018-12-31 $0.59B $2.79B 22.66%
2018-09-30 $0.54B $2.69B 22.36%
2018-06-30 $0.71B $2.57B 31.32%
2018-03-31 $0.48B $2.37B 23.28%
2017-12-31 $0.42B $2.10B 20.87%
2017-09-30 $0.51B $2.07B 26.23%
2017-06-30 $0.40B $1.78B 20.98%
2017-03-31 $0.66B $2.07B 34.76%
2016-12-31 $0.71B $1.85B 39.62%
2016-09-30 $0.71B $1.84B 40.83%
2016-06-30 $1.01B $1.81B 61.52%
2016-03-31 $0.90B $1.71B 62.26%
2015-12-31 $0.65B $1.59B 50.19%
2015-09-30 $0.66B $1.47B 54.70%
2015-06-30 $0.17B $1.04B 15.20%
2015-03-31 $0.19B $1.09B 15.87%
2014-12-31 $0.34B $1.24B 27.77%
2014-09-30 $0.20B $1.18B 15.82%
2014-06-30 $0.28B $1.17B 22.60%
2014-03-31 $0.25B $1.32B 20.08%
2013-12-31 $0.18B $1.26B 14.48%
2013-09-30 $0.29B $1.26B 24.72%
2013-06-30 $0.30B $1.17B 27.17%
2013-03-31 $0.30B $1.15B 27.40%
2012-12-31 $0.30B $1.08B 29.09%
2012-09-30 $0.26B $1.06B 26.11%
2012-06-30 $0.27B $1.01B 26.55%
2012-03-31 $0.27B $1.03B 26.80%
2011-12-31 $0.22B $0.95B 21.92%
2011-09-30 $0.18B $1.09B 18.90%
2011-06-30 $0.14B $1.00B 15.34%
2011-03-31 $0.10B $0.92B 12.12%
2010-12-31 $0.11B $0.88B 13.23%
2010-09-30 $0.09B $0.84B 12.52%
2010-06-30 $0.07B $0.78B 9.42%
2010-03-31 $0.03B $0.73B 3.96%
2009-12-31 $0.02B $0.65B 3.23%
2009-09-30 $-0.06B $0.64B -9.93%
2009-06-30 $-0.06B $0.61B -11.13%
2009-03-31 $-0.05B $0.58B -9.61%
2008-12-31 $-0.05B $0.56B -11.79%
2008-09-30 $0.03B $0.42B 7.69%
2008-06-30 $0.03B $0.36B 10.37%
2008-03-31 $0.03B $0.33B 9.88%
2007-12-31 $0.01B $0.30B 5.73%
2007-09-30 $0.07B $0.21B 39.68%
2007-06-30 $0.07B $0.18B 33.09%
2007-03-31 $0.07B $0.15B 29.65%
2006-12-31 $0.07B $0.21B 27.79%
2006-09-30 $0.05B $0.28B 16.56%
2006-06-30 $0.06B $0.30B 20.04%
2006-03-31 $0.06B $0.29B 23.25%
2005-12-31 $0.07B $0.28B 27.87%
2005-09-30 $0.04B $0.24B 20.24%
2005-06-30 $0.03B $0.22B 16.69%
2005-03-31 $0.03B $0.20B 13.42%
2004-12-31 $0.02B $0.19B 8.49%
2004-09-30 $0.01B $0.18B 2.93%
2004-06-30 $0.00B $0.17B -1.19%
2004-03-31 $-0.01B $0.17B -4.76%
2003-12-31 $-0.01B $0.17B -5.33%
2003-09-30 $-0.01B $0.17B -5.30%
2003-06-30 $-0.02B $0.17B -11.71%
2003-03-31 $-0.02B $0.17B -12.00%
2002-12-31 $-0.02B $0.17B -13.28%
2002-09-30 $-0.03B $0.17B -14.99%
2002-06-30 $-0.03B $0.19B -13.38%
2002-03-31 $-0.03B $0.19B -16.89%
2001-12-31 $-0.04B $0.20B -17.64%
2001-09-30 $-0.06B $0.20B -28.25%
2001-06-30 $-0.06B $0.21B -25.74%
2001-03-31 $-0.08B $0.23B -37.65%
2000-12-31 $-0.08B $0.24B -42.40%
2000-09-30 $-0.05B $0.24B -39.55%
2000-06-30 $-0.05B $0.12B -59.09%
2000-03-31 $-0.03B $0.12B -39.32%
1999-12-31 $-0.03B $0.05B -77.19%
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $20.018B $2.877B
United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $85.303B 32.40
Zoetis (ZTS) United States $54.932B 19.66
Takeda Pharmaceutical (TAK) Japan $51.421B 10.49
Daiichi Sankyo, - (DSNKY) Japan $39.630B 19.74
BeOne Medicines - (ONC) Switzerland $37.087B 196.62
Sandoz Group AG (SDZNY) Switzerland $33.939B 0.00
Merck (MKKGY) Germany $19.496B 12.02
Shionogi (SGIOY) Japan $15.261B 14.02
Neurocrine Biosciences (NBIX) United States $13.200B 31.67
Summit Therapeutics (SMMT) United States $13.140B 0.00
IPSEN (IPSEY) France $13.109B 0.00
Ionis Pharmaceuticals (IONS) United States $12.364B 0.00
Madrigal Pharmaceuticals (MDGL) United States $11.394B 0.00
Orion OYJ (ORINY) Finland $10.204B 29.15
Eisai (ESAIY) $8.236B 0.00
Ono Pharmaceutical (OPHLF) Japan $6.576B 20.00
Grifols, S.A (GRFS) Spain $6.112B 0.00
Stevanato Group S.p.A (STVN) Italy $5.981B 33.47
Crinetics Pharmaceuticals (CRNX) United States $5.313B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.613B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.216B 20.01
Indivior (INDV) United States $4.068B 16.60
Corcept Therapeutics (CORT) United States $3.653B 39.47
NewAmsterdam Pharma (NAMS) Netherlands $3.589B 0.00
Hypermarcas (HYPMY) Brazil $3.047B 20.91
Centessa Pharmaceuticals (CNTA) United Kingdom $2.984B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.790B 8.90
Ocular Therapeutix (OCUL) United States $2.401B 0.00
Dyne Therapeutics (DYN) United States $2.386B 0.00
Soleno Therapeutics (SLNO) United States $2.282B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $2.098B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.958B 23.20
Harrow (HROW) United States $1.774B 108.86
Guardian Pharmacy Services (GRDN) United States $1.712B 32.96
Ardelyx (ARDX) United States $1.640B 0.00
Oruka Therapeutics (ORKA) United States $1.617B 0.00
Enliven Therapeutics (ELVN) United States $1.585B 0.00
Amylyx Pharmaceuticals (AMLX) United States $1.570B 0.00
Collegium Pharmaceutical (COLL) United States $1.441B 7.14
BioCryst Pharmaceuticals (BCRX) United States $1.404B 83.25
Evotec AG (EVO) Germany $1.282B 0.00
Relay Therapeutics (RLAY) United States $1.274B 0.00
Xeris Biopharma Holdings (XERS) United States $1.248B 0.00
Savara (SVRA) United States $1.184B 0.00
ARS Pharmaceuticals (SPRY) United States $1.051B 0.00
Theravance Biopharma (TBPH) United States $1.014B 42.57
Aktis Oncology (AKTS) United States $1.000B 0.00
Cronos Group (CRON) Canada $0.967B 0.00
Xencor (XNCR) United States $0.913B 0.00
Nektar Therapeutics (NKTR) United States $0.766B 0.00
KalVista Pharmaceuticals (KALV) United States $0.738B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.732B 17.31
Esperion Therapeutics (ESPR) United States $0.727B 0.00
ProKidney (PROK) United States $0.689B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.680B 6.07
Bioventus (BVS) United States $0.656B 13.44
Lexeo Therapeutics (LXEO) United States $0.539B 0.00
Elite Pharmaceuticals (ELTP) United States $0.506B 0.00
Lyell Immunopharma (LYEL) United States $0.505B 0.00
Zevra Therapeutics (ZVRA) United States $0.503B 0.00
Organogenesis (ORGO) United States $0.481B 0.00
Siga Technologies (SIGA) United States $0.471B 6.45
Altimmune (ALT) United States $0.442B 0.00
4D Molecular Therapeutics (FDMT) United States $0.431B 0.00
Nature's Sunshine Products (NATR) United States $0.421B 25.07
Aquestive Therapeutics (AQST) United States $0.404B 0.00
USANA Health Sciences (USNA) United States $0.401B 11.19
Cybin (HELP) Canada $0.386B 0.00
Akebia Therapeutics (AKBA) United States $0.361B 0.00
Achieve Life Sciences (ACHV) Canada $0.310B 0.00
Profound Medical (PROF) Canada $0.298B 0.00
Aclaris Therapeutics (ACRS) United States $0.284B 0.00
Avalo Therapeutics (AVTX) United States $0.279B 0.00
Aldeyra Therapeutics (ALDX) United States $0.279B 0.00
Relmada Therapeutics (RLMD) United States $0.274B 0.00
OmniAb (OABI) United States $0.274B 0.00
Heron Therapeutics (HRTX) United States $0.273B 0.00
Fractyl Health (GUTS) United States $0.262B 0.00
Larimar Therapeutics (LRMR) United States $0.259B 0.00
Protara Therapeutics (TARA) United States $0.259B 0.00
Silence Therapeutics (SLN) United Kingdom $0.238B 0.00
Enlivex Therapeutics (ENLV) Israel $0.223B 0.00
Journey Medical (DERM) United States $0.217B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.209B 0.00
MediWound (MDWD) Israel $0.209B 0.00
Galectin Therapeutics (GALT) United States $0.196B 0.00
Minerva Neurosciences (NERV) United States $0.193B 0.00
Century Therapeutics (IPSC) United States $0.190B 0.00
Innate Pharma SA (IPHYF) France $0.181B 0.00
Surrozen (SRZN) United States $0.171B 0.00
AleAnna (ANNA) United States $0.171B 0.00
VAXART, INC (VXRT) United States $0.169B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.161B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.146B 0.00
Unicycive Therapeutics (UNCY) United States $0.133B 0.00
Context Therapeutics (CNTX) United States $0.132B 0.00
Incannex Healthcare (IXHL) Australia $0.131B 0.00
Inhibikase Therapeutics (IKT) United States $0.126B 0.00
Avita Medical (RCEL) United States $0.119B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.116B 0.00
Karyopharm Therapeutics (KPTI) United States $0.116B 0.00
Prelude Therapeutics (PRLD) United States $0.114B 0.00
Pyxis Oncology (PYXS) United States $0.110B 0.00
Cardiol Therapeutics (CRDL) Canada $0.105B 0.00
Champions Oncology (CSBR) United States $0.100B 42.41
Cassava Sciences (SAVA) United States $0.099B 0.00
Vivani Medical (VANI) United States $0.093B 0.00
Korro Bio (KRRO) United States $0.083B 0.00
Assertio Holdings (ASRT) United States $0.074B 0.00
Gain Therapeutics (GANX) United States $0.070B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.070B 58.12
PolyPid (PYPD) Israel $0.069B 0.00
Dominari Holdings (DOMH) United States $0.069B 0.00
NRx Pharmaceuticals (NRXP) United States $0.067B 0.00
Arch Biopartners (ACHFF) Canada $0.066B 0.00
Rafael Holdings (RFL) United States $0.064B 0.00
Acrivon Therapeutics (ACRV) United States $0.062B 0.00
Metagenomi (MGX) United States $0.062B 0.00
Lipocine (LPCN) United States $0.062B 0.00
PMV Pharmaceuticals (PMVP) United States $0.060B 0.00
ElectroCore (ECOR) United States $0.057B 0.00
Nutriband (NTRB) United States $0.053B 0.00
Lite Strategy (LITS) United States $0.053B 0.00
Telomir Pharmaceuticals (TELO) United States $0.048B 0.00
Talphera (TLPH) United States $0.047B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.041B 0.00
Plus Therapeutics (PSTV) United States $0.040B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Wellgistics Health (WGRX) United States $0.036B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.030B 0.00
Jupiter Neurosciences (JUNS) United States $0.030B 0.00
Natural Alternatives (NAII) United States $0.029B 0.00
SCYNEXIS (SCYX) United States $0.027B 0.00
TherapeuticsMD (TXMD) United States $0.026B 0.00
Klotho Neurosciences (KLTO) United States $0.024B 0.00
Scienture Holdings (SCNX) United States $0.022B 0.00
Liminatus Pharma (LIMN) United States $0.021B 0.00
Cosmos Health (COSM) United States $0.020B 0.00
Vivos Therapeutics (VVOS) United States $0.020B 0.00
Inotiv (NOTV) United States $0.020B 0.00
VYNE Therapeutics (VYNE) United States $0.019B 0.00
Iterum Therapeutics (ITRM) Ireland $0.018B 0.00
Citius Pharmaceuticals (CTXR) United States $0.018B 0.00
Traws Pharma (TRAW) United States $0.016B 0.02
Vyome Holdings (HIND) United States $0.016B 0.00
Mannatech (MTEX) United States $0.014B 0.00
Tempest Therapeutics (TPST) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.013B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
CASI Pharmaceuticals (CASI) China $0.012B 0.00
China SXT Pharmaceuticals (SXTC) China $0.011B 0.00
Addex Therapeutics (ADXN) Switzerland $0.010B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.010B 0.00
Mangoceuticals (MGRX) United States $0.010B 0.00
Ernexa Therapeutics (ERNA) United States $0.010B 0.00
Ainos (AIMD) United States $0.009B 0.00
BioVie (BIVI) United States $0.009B 0.00
Nuvilex (PMCB) United States $0.009B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Heatwurx (PCSA) United States $0.008B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Indaptus Therapeutics (INDP) United States $0.007B 0.00
Alaunos Therapeutics (TCRT) United States $0.007B 0.00
Redhill Biopharma (RDHL) Israel $0.007B 0.00
Aptorum Group (APM) United Kingdom $0.007B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Jaguar Animal Health (JAGX) United States $0.005B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Lyra Therapeutics (LYRA) United States $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Universe Pharmaceuticals INC (UPC) China $0.003B 0.00
CDT Equity (CDT) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00